Shutoku Matsuyama


Affiliation: National Institute of Infectious Diseases
Country: Japan


  1. Matsuyama S, Shirato K, Kawase M, Terada Y, Kawachi K, Fukushi S, et al. Middle East Respiratory Syndrome Coronavirus Spike Protein Is Not Activated Directly by Cellular Furin during Viral Entry into Target Cells. J Virol. 2018;92: pubmed publisher
    ..Here we describe appropriate experiments that can be used to assess the effect of protease inhibitors on virus cell entry. ..
  2. Matsuyama S, Taguchi F. Two-step conformational changes in a coronavirus envelope glycoprotein mediated by receptor binding and proteolysis. J Virol. 2009;83:11133-41 pubmed publisher
    ..These results suggest that trypsin suffices for the induction of membrane fusion of receptor-primed S protein, but an additional unidentified cellular factor is required to trigger membrane fusion by CPL. ..
  3. Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, Taguchi F. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol. 2010;84:12658-64 pubmed publisher
    ..Our findings suggest that the TMPRSS2 expressed in lung tissues may be a determinant of viral tropism and pathogenicity at the initial site of SARS-CoV infection...
  4. Shirato K, Kanou K, Kawase M, Matsuyama S. Clinical Isolates of Human Coronavirus 229E Bypass the Endosome for Cell Entry. J Virol. 2017;91: pubmed
    ..Therefore, therapeutic agents for coronavirus-mediated diseases, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), should target cell surface TMPRSS2 rather than endosomal cathepsin. ..